Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogenerics Are Happening: Slowly, Product-By-Product

This article was originally published in RPM Report

Executive Summary

FDA's guidance on biogenerics is on the backburner: Congress is showing little interest in pushing the agency towards them. But some follow-on products are already making it to the market.

Related Content

A Transparency Case Study: Horizant Approval for RLS Offers Window Into Complexity of Complete Response Disclosures
European Biosimilars' Market Performance Mirrors US Legislative Progress: Slow but Steady
Betting Generic: Part D, Patents and Proteins Drive Investment Surge
Welcome to the P&T Committee: Reining in Biotech Prices
Omnitrope Clears FDA: Is the Next Hurdle Congress?
A CERA-ous Challenge to Amgen's EPO Franchise?
Forced to Act: Omnitrope and the Battle for an FDA Commissioner
Biosimilars: The Time Has Come
Biogenerics: A Step Closer
Biogenerics Are Coming and They're Not the Generics We Know


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts